Simon Dearden

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Kenneth S. Thress, Roz Brant, T. Hedley Carr et al. · Lung Cancer · 2015 · 489 citations · Full text

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Jean‐Yves Douillard, Gyula Ostoros, Manuel Cobo et al. · Journal of Thoracic Oncology · 2014 · 441 citations · Full text

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong et al. · Clinical Cancer Research · 2019 · 126 citations · Full text

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

Ruth Board, Gillian Ellison, Maria Orr et al. · British Journal of Cancer · 2009 · 100 citations · Full text

Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N., Alan Barnicle, Caroline Sibilla et al. · Clinical Cancer Research · 2022 · 62 citations · Full text